Experience with sorafenib in the treatment of advanced renal cell carcinoma

Therapeutic Advances in Urology

Volumn 4, Issue 6, 2012, Pages 303-313

  Procopio, Giuseppe ^a   Verzoni, Elena ^a   Testa, Isabella ^a   Nicolai, Nicola ^a   Salvioni, Roberto ^a   Debraud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

First line treatment; older people; renal cell carcinoma; sorafenib; targeted therapies

Indexed keywords

ALPHA INTERFERON; AXITINIB; EVEROLIMUS; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TIVOZANIB; TREBANANIB;

ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; KIDNEY FAILURE; OVERACTIVE BLADDER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME;

EID: 84868237540     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212457216     Document Type: Article

References (54)

1. Aveo-Astellas (2011) Aveo and Astellas announce tivozanib successfully demonstrated progression-free survival superiority over sorafenib in patients with advanced renal cell cancer in phase 3 tivo-1 trial. Available at: http://www.astellas.com/en/corporate/news/detail/aveo-and-astellas-announce-tiv.html (accessed 9 May 2012).
2. Awada A. Hendlisz A. Christensen O. Lathia C. Bartholomeus S. Lebrun F. (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48: 465–474.
3. Beck J. Procopio G. Bajetta E. Keilholz U. Negrier S. Szczylik C. (2011) Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22: 1812–1823.
4. Bellmunt J. Fishman M. Eisen T. Quinn D. (2010a) Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther 10: 825–835.
5. Bellmunt J. Maroto-Rey P. Trigo J. Carles J. Guillem V. Lopez-Martin J. (2010b) A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG study 06-01. Clin Transl Oncol 12: 503–508.
6. Bellmunt J. Negrier S. Escudier B. Awada A. Aapro M. (2009) The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 69: 64–72.
7. Bukowski R.M. Stadler W.M. McDermott W.F. Dutcher J.P. Knox J.J. Miller W.H. (2010) Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78: 340–347
8. Castagneto B. Stevani I. Giorcelli L. Montefiore F. Bigatti G. Pisacco P. (2011) Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Med Oncol 28: 1384–1388.
9. Cheng H. Kari G. Dicker A. Rodeck U. Koch W. Force T. (2011) A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 109: 1401–1409.
10. Clark J. Eder J. Ryan D. Lathia C. Lenz H. (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11: 5472–5480.
11. De Reijke T. Bellmunt J. Van Poppel H. Marreaud S. Aapro M. (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45: 765–773.
12. Dutcher J. Tannir N. Bellmunt J. Escudier B. (2010) Experience with sorafenib and the elderly patient. Med Oncol 27: 1359–1370.
13. Eisen T. Oudard S. Szczylik C. Gravis G. Heinzer H. Middleton R. (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100: 1454–1463.
14. European Medicines Agency (2006) Sorafenib approval. Available at: http://www.ema.europa.eu/docs/en_gb/document_library/epar_product_information/human/000690/wc500027704.pdf (accessed 9 May 2012)
15. Escudier B. (2011) Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 11: 825–836.
16. Escudier B. Eisen T. Stadler W. Szczylik C. Oudard S. Siebels M. (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134.
17. Escudier B. Pluzanska A. Koralewski P. Ravaud A. Bracarda S. Szczylik C. (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103–2111.
18. Escudier B. Eisen T. Stadler W. Szczylik C. Oudard S. Staehler M. (2009a) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 27: 3312–3318.
19. Escudier B. Szczylik C. Hutson T. Demkow T. Staehler M. Rolland F. (2009b) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280–1289.
20. Escudier B. Szczylik C. Porta C. Gore M. (2012) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9: 327–337.
21. Gollob J.A. Wilhelm S. Carter C. Kelley S. (2006) Role of Raf Kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392–406.
22. Gore M.E. Szczylik C. Porta C. Bracarda S. Bjarnason G.A. Oudard S. (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8): 757–763.
23. Hudes G. Carducci M. Tomczak P. Dutcher J. Figlin R. Kapoor A. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271–2281.
24. Jäger D. (2012) PREDICT (Patient Characteristics in Renal Cell Carcinoma and Daily Practice Treatment with Sorafenib) global non-interventional study: final report. In: 34th ESMO and 15th ECCO Meeting, Stockholm, Sweden, 2012.
25. Jonasch E. Corn P. Pagliaro L. Warneke C. Johnson M. Tamboli P. (2010) Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116: 57–65.
26. Kirchner H. Strumberg D. Bahl A. Overkamp F. (2010) Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 10: 585–596.
27. Liewen R. Haile S. Siciliano R. Cathomas R. Rothermundt C. Stoll S. (2012) A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 82: 333–340.
28. Masini C. Sabbatini R. Porta C. Procopio G. Di Lorenzo G. Onofri A. (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 24 February 2012 (Epub ahead of print). DOI: 10.1111/j.1464-410X.2012.10946.x
29. Moore M. Hirte H. Siu L. Oza A. Hotte S. Petrenciuc O. (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16: 1688–1694.
30. Motzer R.J. Hutson T.E. Tomczak P. Michaelson M.D. Bukowski R.M. Rixe O. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115–124.
31. National Comprehensive Cancer Network. (2012) V 2 guidelines for management kidney tumor. Available at: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed 9 May 2012).
32. Orphanos G. Ioannidis G. Ardavanis A. (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48: 964–970.
33. Osanto S. Hutson T. Calvo E. Escudier B. Oudard S. Porta C. (2010) Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma. J Clin Oncol 28(suppl. 15): abstract 4608.
34. Paez-Ribes M. Allen E. Hudock J. Takeda T. Okuyama H. Vinals F. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220–231.
35. Parsa V. Heilbrun L. Smith D. Sethi A. Vaishampayan U. (2009) Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 7: E10–E15.
36. Porta C. Paglino C. Imarisio I. (2010) Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur J Clin Med Oncol 12 March 2011 (Epub ahead of print).
37. Procopio G. Verzoni E. Bracarda S. Ricci S. Sacco C. Ridolfi L. (2011a) Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 104: 1256–1261.
38. Procopio G. Verzoni E. Iacovelli R. Guadalupi V. Gelsomino F. Buzzoni R. (2011b) Targeted therapies used sequentially in metastatic renal cell carcinoma: results of a large experience. Expert Rev Anticancer Ther 11: 1631–1640.
39. Ratain M. Eisen T. Stadler W. Flaherty K. Kaye S. Rosner G. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512.
40. Rini B.I. Halabi S. Rosenberg J.E. Stadler W.M. Vaena D.A. Ou S.S. (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33): 5422–5428.
41. Rini B. Escudier B. Tomczak P. Kaprin A. Szczylik C. Hutson T. (2011a) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931–1939.
42. Rini B. Tannir N. Koralewski P. Tomczak A. Deptala K. Kracht Y. (2011b) AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol (Suppl. 7): abstract 309.
43. Ruppin S. Protzel C. Klebingat K. Hakenberg O. (2009) Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol 55: 986–988; quiz 988.
44. Shinsako K. Mizuno T. TeRyarada T. Watanabe J. Kamba T. Nakamura E. (2010) Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 15: 512–514.
45. Sonpavde G. Choueiri T. Escudier B. Ficarra V. Hutson T. Mulders P. (2012) Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61: 307–316.
46. Stadler W. Figlin R. McDermott D. Dutcher J. Knox J. Miller W. Jr. (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272–1280.
47. Sternberg C.N. Szczylik C. Lee E. Salman P.V. Mardiak J. Davis I.D. (2010) A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 28(6): 1061–1068.
48. Strumberg D. Richly H. Hilger R. Schleucher N. Korfee S. Tewes M. (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965–972.
49. Tolcher A. Appleman L. Shapiro G. Mita A. Cihon F. Mazzu A. (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67: 751–764.
50. US Food and Drug Administration (2007) Sorafenib FDA approval. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate (accessed 9 May 2012).
51. US Food and Drug Administration (2011) Oncologic Drugs Advisory Committee Meeting. NDA 202324. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm282290.pdf and http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm283657.pdf (accessed 9 May 2012)
52. Wilhelm S. Adnane L. Newell P. Villanueva A. Llovet J. Lynch M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129–3140.
53. Wilhelm S. Carter C. Lynch M. Lowinger T. Dumas J. Smith R. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835–844.
54. Zustovich F. Lombardi G. Nicoletto O. Pastorelli D. (2011) Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol 83: 112–122.